First Tracks Biotherapeutics Secures $145 Million in Private Placement Financing

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 3 days ago

0mins

ANAB-11.68%

Should l Buy ANAB?

Source: Newsfilter

Financing Size: First Tracks Biotherapeutics has successfully secured $145 million in private placement financing through an agreement with third-party investors, including $80 million in initial proceeds, which is expected to provide ample cash flow to support operations for the next two years.
Equity Sale Details: In this transaction, First Tracks Biotherapeutics is selling 5,791,478 shares of common stock at a price of $13.81 per share, resulting in $80 million in gross proceeds, which will be utilized for general corporate purposes, including clinical development.
Investor Participation: The financing attracted participation from several new and existing investors, including 683 Capital Partners and Adage Capital, demonstrating strong market confidence in First Tracks Biotherapeutics' future growth while providing robust funding support for its product development.
Spin-off Outlook: First Tracks Biotherapeutics plans to complete its spin-off from AnaptysBio on April 20, 2026, and the successful financing will lay the groundwork for its independent operations, providing essential funding for the development of its clinical candidate ANB033.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ANAB?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ANAB

Wall Street analysts forecast ANAB stock price to rise

10 Analyst Rating

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 57.400

Low

50.00

Averages

74.13

High

140.00

Current: 57.400

Low

50.00

Averages

74.13

High

140.00

UBS

Buy

maintain

$70 -> $90

2026-03-17

Reason

UBS

Price Target

$70 -> $90

AI Analysis

2026-03-17

maintain

Buy

Reason

UBS raised the firm's price target on AnaptysBio to $90 from $70 and keeps a Buy rating on the shares. Valuation for the company breaks down to roughly $35-$40 for the royalty business and $45-$50 for the biopharma segment, with interest driven by pipeline upside, particularly the CD122 antagonist ANB033 in celiac disease, which could become a blockbuster and materially lift the stock, the analyst tells investors in a research note.

Truist

Hold

maintain

$36 -> $50

2026-03-09

Reason

Truist

Price Target

$36 -> $50

2026-03-09

maintain

Hold

Reason

Truist raised the firm's price target on AnaptysBio to $50 from $36 and keeps a Hold rating on the shares. The firm is updating its target to reflect the company's Q4 update that pulled forward the timing of the spin-off to late April, the analyst tells investors in a research note. AnaptysBio Q4 revenue beat was also mostly Jemperli milestone driven, Truist notes, adding however that its hold rating is due to poor pipeline outlook and GSK/Tesaro suit overhang.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANAB

Unlock Now

About ANAB

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

AnaptysBio Approves Spin-Off of First Tracks Biotherapeutics

3 days agoseekingalpha

Spin-Off Announcement: AnaptysBio has approved the spin-off of First Tracks Biotherapeutics, with the new entity expected to begin trading on Nasdaq under the ticker “TRAX” on April 20, 2026, potentially unlocking new market opportunities.
Financial Management: Post-spin-off, AnaptysBio will manage financial collaborations for Jemperli with GSK and imsidolimab with Vanda, ensuring the continued development and competitiveness of its core product lines.
Financial Position: The new company will launch operations with approximately $140-$145 million in net cash and investments while maintaining limited full-time employees and minimal operating expenses to achieve efficient financial management.
Stock Repurchase Plan: AnaptysBio has also announced a $100 million stock repurchase plan aimed at buying back outstanding common stock, which could enhance shareholder value and boost market confidence.

AnaptysBio Announces $100 Million Buyback and Business Update

3 days agoNASDAQ.COM

Buyback Plan: AnaptysBio's board has authorized a stock repurchase plan of up to $100 million, aimed at enhancing shareholder value and boosting market confidence.
Business Restructuring: The company plans to spin off its biopharma operations into First Tracks Biotherapeutics by April 20, focusing on financial collaborations with GSK and Vanda, which is expected to free up resources for core operations.
Financial Position: Post-spin-off, AnaptysBio anticipates having between $140 million and $145 million in net cash and investments, ensuring financial flexibility for future operations.
Operational Efficiency: The company aims to keep annual operating expenses below $10 million while achieving an EBIT margin exceeding 95%, supporting sustainable growth and profitability.

Anaptys Announces Spin-Off of Biopharma Operations

3 days agoNewsfilter

Biopharma Spin-Off: Anaptys plans to spin off its biopharma operations into First Tracks Biotherapeutics on April 20, 2026, aiming to enhance overall financial performance by focusing on protecting and returning shareholder value.
Stock Repurchase Plan: The company announced a stock repurchase plan of up to $100 million, expected to repurchase common stock through market transactions, thereby boosting shareholder confidence and enhancing shareholder value.
Board Expansion: Anaptys appointed Susannah Gray, former CFO of Royalty Pharma, to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical sector, which will provide valuable financial and capital markets expertise to the company.
Operational Model Optimization: Post-spin-off, Anaptys will adopt a virtual operating model with anticipated annual operating expenses of less than $10 million and an EBIT margin exceeding 95%, ensuring efficient financial management and resource allocation.